Arca Biopharma | ABIO - Operating Profit


Arca Biopharma reported $-36.43M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Amgen USD 4.68B 65M Sep/2026
Arca Biopharma USD -36.43M 2M Mar/2026
Biogen USD 419.5M 663.3M Sep/2026
Brainstorm Cell Therapeutics USD -2.05M 198K Mar/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cipla INR 10.43B 1.55B Sep/2026
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -8.84M 180K Jun/2026
CSL USD 2.64B 1.97B Dec/2025
Cytokinetics USD -167.09M 12.08M Sep/2026
Daiichi Sankyo JPY 108.7B 23.6B Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Grifols EUR 320.55M 91.01M Dec/2025
Laboratory Of America USD 418M 38.7M Sep/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Otsuka Holdings JPY 142.24B 1.83B Sep/2026
Pfizer USD 662M 5M Sep/2026
United Therapeutics USD 241.3M 89.5M Sep/2026